Cargando…

Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion

Muscle-invasive bladder cancer (MIBC) consists of a heterogeneous group of tumors with a high rate of metastasis and mortality. To facilitate the in-depth investigation and validation of tailored strategies for MIBC treatment, we have developed an integrated approach using advanced high-throughput d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Nakho, Lee, Hye Won, Lim, Joung Eun, Jeong, Da Eun, Song, Hye Jin, Kim, Sudong, Nam, Do-Hyun, Sung, Hyun Hwan, Jeong, Byong Chang, Seo, Seong Il, Jeon, Seong Soo, Lee, Hyun Moo, Choi, Han-Yong, Jeon, Hwang Gyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239502/ https://www.ncbi.nlm.nih.gov/pubmed/27438149 http://dx.doi.org/10.18632/oncotarget.10539

Ejemplares similares

Curcumin potentiates antitumor activity of cisplatin in bladder cancer cell lines via ROS-mediated activation of ERK1/2
por: Park, Bong Hee, et al.
Publicado: (2016)

Diagnostic and Prognostic Significance of Radiologic Node-positive Renal Cell Carcinoma in the Absence of Distant Metastases: A Retrospective Analysis of Patients Undergoing Nephrectomy and Lymph Node Dissection
por: Lee, Hye Won, et al.
Publicado: (2015)

Comparison of Pathological and Biochemical Outcomes after Radical Prostatectomy in Korean Patients with Serum PSA Ranges
por: Lee, Hye Won, et al.
Publicado: (2015)

Is Radical Perineal Prostatectomy a Viable Therapeutic Option for Intermediate- and High-risk Prostate Cancer?
por: Lee, Hye Won, et al.
Publicado: (2015)

Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer
por: Song, Wan, et al.
Publicado: (2016)

Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance
por: Yu, Jiwoong, et al.
Publicado: (2021)

Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis
por: Jeong, Da Eun, et al.
Publicado: (2015)

PKI uncovered
por: Karamanian, Andre, et al.
Publicado: (2011)

PKI-587 enhances radiosensitization of hepatocellular carcinoma by inhibiting the PI3K/AKT/mTOR pathways and DNA damage repair
por: Xie, Yinghai, et al.
Publicado: (2021)

Integrative Radiogenomics Approach for Risk Assessment of Post-Operative Metastasis in Pathological T1 Renal Cell Carcinoma: A Pilot Retrospective Cohort Study
por: Lee, Hye Won, et al.
Publicado: (2020)

The clinical utility of transperineal template-guided saturation prostate biopsy for risk stratification after transrectal ultrasound-guided biopsy
por: Song, Wan, et al.
Publicado: (2019)

Laparoendoscopic single-site simple nephrectomy using a magnetic anchoring system in a porcine model
por: Choi, Young Hyo, et al.
Publicado: (2016)

Correlation between Gleason score distribution and Prostate Health Index in patients with prostate-specific antigen values of 2.5–10 ng/mL
por: Choi, Joongwon, et al.
Publicado: (2020)

Diagnostic Ureterorenoscopy Is Associated with Increased Intravesical Recurrence following Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma
por: Sung, Hyun Hwan, et al.
Publicado: (2015)

Influence of Body Mass Index, Smoking, and Blood Pressure on Survival of Patients with Surgically-Treated, Low Stage Renal Cell Carcinoma: A 14-Year Retrospective Cohort Study
por: Park, Bumsoo, et al.
Publicado: (2013)

Pure Laparoscopic Radical Cystectomy with Ileal Conduit: A Single Surgeon's Mid-Term Outcomes
por: Park, Bumsoo, et al.
Publicado: (2013)

Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia
por: Hong, Ji Hyung, et al.
Publicado: (2015)

Detection of prostate cancer using prostate imaging reporting and data system score and prostate-specific antigen density in biopsy-naive and prior biopsy-negative patients
por: Ryoo, Hyunsoo, et al.
Publicado: (2020)

Clinical Significance of Pre-to-Postoperative Dynamics of Aspartate Transaminase/Alanine Transaminase Ratio in Predicting the Prognosis of Renal Cell Carcinoma after Surgical Treatment
por: Kang, Minyong, et al.
Publicado: (2020)

The clinical usefulness of natural killer cell activity in patients with suspected or diagnosed prostate cancer: an observational cross-sectional study
por: Song, Wan, et al.
Publicado: (2018)

Incidences and oncological outcomes of urothelial carcinoma in kidney transplant recipients
por: Yu, Jiwoong, et al.
Publicado: (2018)

Location of Positive Surgical Margin and Its Association With Biochemical Recurrence Rate Do Not Differ Significantly in Four Different Types of Radical Prostatectomy
por: Suh, Yoon Seok, et al.
Publicado: (2014)

Outcome of Prostate Biopsy in Men Younger than 40 Years of Age with High Prostate-Specific Antigen (PSA) Levels
por: Yang, Jin Bak, et al.
Publicado: (2010)

Predictive factors of unfavorable prostate cancer in patients who underwent prostatectomy but eligible for active surveillance
por: Choo, Seol Ho, et al.
Publicado: (2014)

Histological characteristics of the largest and secondary tumors in radical prostatectomy specimens and implications for focal therapy
por: Choi, Young Hyo, et al.
Publicado: (2019)

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
por: D'Amato, V, et al.
Publicado: (2014)

Comparison of oncologic and functional outcomes between radical nephroureterectomy and segmental ureterectomy for upper urinary tract urothelial carcinoma
por: Kim, Tae Heon, et al.
Publicado: (2021)

Conditional Intravesical Recurrence-Free Survival Rate After Radical Nephroureterectomy With Bladder Cuff Excision for Upper Tract Urothelial Carcinoma
por: Chung, Jae Hoon, et al.
Publicado: (2021)

A Comparison of Functional and Oncologic Outcomes between Partial Nephrectomy and Radiofrequency Ablation in Patients with Chronic Kidney Disease after Propensity Score Matching
por: Ryoo, Hyunsoo, et al.
Publicado: (2022)

A Comparison of Surgical and Functional Outcomes of Robot-Assisted Versus Pure Laparoscopic Partial Nephrectomy
por: Choi, Jae Duck, et al.
Publicado: (2013)

Public key infrastructure: (PKI)
por: Roebuck, Kevin
Publicado: (2011)

Effects of Complete Bladder Cuff Removal on Oncological Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma
por: Ryoo, Hyunsoo, et al.
Publicado: (2021)

Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value
por: Chung, Jae Hoon, et al.
Publicado: (2021)

Interval from Prostate Biopsy to Radical Prostatectomy Does Not Affect Immediate Operative Outcomes for Open or Minimally Invasive Approach
por: Park, Bumsoo, et al.
Publicado: (2014)

Incidence and Predictive Factors of Benign Renal Lesions in Korean Patients with Preoperative Imaging Diagnoses of Renal Cell Carcinoma
por: Park, Seo Yong, et al.
Publicado: (2011)

Utility of multiple core biopsies during transperineal template-guided mapping biopsy for patients with large prostates and PI-RADS 1–2 on multiparametric magnetic resonance imaging
por: Lee, Chung Un, et al.
Publicado: (2022)

Assessment of Agreement between Two Difference Prostate-Specific Antigen Assay Modalities
por: Chung, Jae Hoon, et al.
Publicado: (2021)

Correction: Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value
por: Chung, Jae Hoon, et al.
Publicado: (2022)

Transperitoneal radical nephroureterectomy is associated with worse disease progression than retroperitoneal radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma
por: Kim, Tae Heon, et al.
Publicado: (2019)

Strategy for Prostate Cancer Patients with Low Prostate Specific Antigen Level (2.5 to 4.0 ng/mL)
por: Chung, Jae Hoon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h7c85h1pebklegu3pjhh9j9red